Business Wire

Toshiba Memory Corporation Develops New Bridge Chip Using PAM 4 to Boost SSD Speed and Capacity

Jaa

Toshiba Memory Corporation, the world leader in memory solutions, today announced the development of a bridge chip that realizes high-speed and large-capacity SSDs. Using developed bridge chips with a small occupied area and low-power consumption, the company has succeeded in connecting more flash memory chips with fewer high-speed signal lines than with the conventional method of no bridge chips. This result was announced in San Francisco on February 20, at the International Solid-State Circuits Conference 2019 (ISSCC 2019).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005378/en/

Fig. 1 Connection using bridge chips (Graphic: Business Wire)

Fig. 1 Connection using bridge chips (Graphic: Business Wire)

In SSDs, multiple flash memory chips are connected to a controller that manages their operation. As more flash memory chips are connected to a controller interface, operating speed degrades, so there are limits to the number of chips that can be connected. In order to increase capacity, it is necessary to increase the number of interfaces, but that results in an enormous number of high-speed signal lines connected to the controller, making it more difficult to implement the wiring on the SSD board.

The company has overcome this problem with the development of a bridge chip that connects the controller and flash memory chips (Fig. 1), three novel techniques: a daisy chains*1 connection including the controller and bridge chips in a ring shape; a serial communication using PAM 4*2; and a jitter*3 improvement technique for eliminating a PLL circuit*4 in the bridge chips. By using these techniques overhead of the bridge chips is reduced, and it is possible to operate a large number of flash memory chips at high speed with only a few high-speed signal lines (Fig. 2).

The ring-shape configuration of the bridge chips and the controller reduces the number of transceivers required in the bridge chip from two pairs to one pair, it achieves chip area reduction of the bridge chip. In addition, adopting PAM 4 serial communication between the controller and the daisy-chained bridge chips lowers the operating speed in the bridge chips’ circuits and relaxes their required performance. A new CDR*5 that utilizes the characteristics of PAM 4 to improve jitter characteristics eliminates the need for a PLL circuit in the bridge chip, which also contributes to a smaller chip area and lower power consumption.

The prototype bridge chips were fabricated with 28nm CMOS process, and results were evaluated by connecting four bridge chips and a controller in ring-shape daisy chain. This confirmed satisfactory performance of PAM 4 communication by all of the bridge chips and the controller at 25.6 Gbps, and also that it is possible to obtain a BER*6 of less than 10-12.

Moving forward, the company will continue development work toward achieving high-speed, large-capacity storage at levels not yet seen by further enhancing bridge-chip performance while reducing the chip’s area and power consumption.

Notes
*1 Daisy chain: a connecting scheme in which multiple chips are wired together in sequence
*2 PAM 4: 4-level Pulse Amplitude Modulation (it contains a 4-value data)
*3 Jitter: Fluctuation in the time domain of the clock or signal waveforms
*4 PLL: Phase Locked Loop (a circuit that generates an accurate reference signal)
*5 CDR: Clock Data Recovery (a circuit that recovers the data and clock from the received signal)
*6 BER: Bit Error Rate (the lower value is the better performance)

About Toshiba Memory Corporation

Toshiba Memory Corporation, a world leader in memory solutions, is dedicated to the development, production and sales of flash memory and SSDs. In June 2018, Toshiba Memory was acquired by an industry consortium led by Bain Capital. Toshiba Memory pioneers cutting-edge memory solutions and services that enrich people's lives and expand society's horizons. The company's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high density applications including advanced smartphones, PCs, SSDs, automotive and data centers. For more information on Toshiba Memory, please visit https://business.toshiba-memory.com/en-apac/top.html

Contact information

Toshiba Memory Corporation
Kota Yamaji
Business Planning Division
Phone: +81-3-6478-2319
semicon-NR-mailbox@ml.toshiba.co.jp

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 23:30:00 EETTiedote

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in

AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 22:50:00 EETTiedote

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin

Historic Partnership between the Weizmann Institute of Science and Institut Curie25.3.2019 19:54:00 EETTiedote

On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics. Collaborative research programs This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot.

Bidgely EV Solution Detects Charging Patterns for Vehicle-to-Grid Integration25.3.2019 19:36:00 EETTiedote

Bidgely today introduced an Electric Vehicle (EV) Solution for global utilities that applies artificial intelligence and machine learning to customer data for smart vehicle-to-grid (V2G) integration. With Bidgely’s industry-leading EV disaggregation patent serving as the foundation, the new EV Solution identifies territory-wide residential charging patterns and pinpoints homes with EVs for targeted product and service offerings that help utilities enhance customer engagement, manage the grid more effectively and generate new revenue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005621/en/ The new Bidgely EV Solution identifies territory-wide residential charging patterns and pinpoints homes with EVs for targeted product and service offerings that help utilities enhance customer engagement, manage the grid more effectively and generate new revenue. (Graphic: Business Wire) “Beneficial electrification, and EVs in parti

The International Society for Quality in Health Care Partners with the Patient Safety Movement Foundation to Achieve Zero Preventable Deaths in Hospitals25.3.2019 19:30:00 EETTiedote

The International Society for Quality in Health Care (ISQua) is pleased to announce their support of the Patient Safety Movement Foundation (PSMF) and their mission to eliminate preventable deaths in hospitals, with a signed cooperation agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005265/en/ With this agreement, ISQua and PSMF agree to work together to further their aims to improve quality and safety in healthcare and eliminate preventable patient deaths. The partnership will provide synergy so that our missions can be amplified. ISQua and PSMF will work together to identify common projects in the field of patient safety and promote each other’s activities on an ongoing basis. ISQua and PSMF will hold joint sessions at their respective conferences, at ISQua’s 36th International Conference (20th – 23rd October 2019) in Cape Town, South Africa; and PSMF’s 8th Annual World Patient Safety, Science & Technology

The Results Are In! BOC Group Named a Leader in the Enterprise Architecture Management Suites, Q1 2019 report by Independent Research Firm25.3.2019 16:32:00 EETTiedote

BOC Group, the leading global provider of Enterprise Management Solutions, announced today that it has been recognized as a “Leader” in The Forrester Wave™: Enterprise Architecture Management Suites, Q1 2019 report. Evaluated against 35 rigorous criteria, BOC Group’s EA suite ADOIT received the highest possible scores in 16 of them, including customer satisfaction, innovation agenda criteria and many others! Christoph Moser, ADOIT product manager, comments on this accomplishment by saying: “We see this achievement as an affirmation of our unwavering position as a front-runner in the EA industry and a direct reflection of the strength, depth and breadth we have incorporated across all aspects of our comprehensive, user-centric EA offering and portfolio in the last years.” Moser continues: “For us, this recognition is hard-earned and well deserved. But more importantly, we believe it further proves our strategy, relentless commitment to our customers, and continued mission to enable orga

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme